ASTHMA, a chronic pulmonary condition characterized by reversible airway obstruction, is one of the hallmark diseases of childhood in the United States ([@bib120]). Asthma is also the most disparate common disease in the pediatric clinic, with significant variation in prevalence, morbidity, and mortality among U.S. racial/ethnic groups ([@bib82]). Specifically, African American children carry a higher asthma disease burden compared to their European American counterparts ([@bib2]; [@bib1]). Forced expiratory volume in the first second (FEV~1~), a measurement of lung function, is a vital clinical trait used by physicians to assess overall lung health and diagnose pulmonary diseases such as asthma ([@bib52]). We have previously shown that genetic ancestry plays an important role in FEV~1~ variation and that African Americans have lower FEV~1~ compared to European Americans, regardless of asthma status ([@bib59]; [@bib88]). The disparity in lung function between populations may explain disparities in asthma disease burden. Understanding the factors that influence FEV~1~ variation among individuals with asthma could lead to improved patient care and therapeutic interventions.

Twin and family-based studies estimate that the heritability of FEV~1~ ranges from 26 to 81%, supporting the combined contribution by genetic and environmental factors in FEV~1~ variation ([@bib21]; [@bib22]; [@bib86]; [@bib45]; [@bib121]; [@bib99]; [@bib106]). Genome-wide association studies (GWAS) of FEV~1~, including among individuals with asthma, have identified many variants that contribute to lung function ([@bib94]; [@bib101], [@bib102]; [@bib62]; [@bib63]; [@bib113]). A search in the National Human Genome Research Institute-European Bioinformatics Institute (NHGRI-EBI) GWAS Catalog (version e98_r2020-03-08) on baseline lung function (FEV~1~) alone revealed 349 associations ([@bib16]). However, most of these previous GWAS were performed in adult populations of European descent, and their results may not generalize across populations or across the life span of an individual ([@bib19]; [@bib69]; [@bib119]). Previous GWAS results are also limited due to their reliance on genotyping arrays. In particular, variation in noncoding regions of the genome is not adequately covered by many genotyping arrays because they were not designed to account for the population-specific genetic variability of all populations ([@bib123]; [@bib56]). Whole-genome sequencing (WGS) is a newer technology that captures nearly all common variation from coding and noncoding regions of the genome, and is unencumbered by genotype array design constraints and differences in linkage disequilibrium (LD) patterns among populations. To date, no large-scale WGS studies of lung function have been performed in African American children with asthma ([@bib69]).

In addition to genetics, FEV~1~ is a complex trait that is significantly influenced by both genetic variation and environmental factors, such as air pollution ([@bib21]; [@bib86]; [@bib45]; [@bib121]; [@bib106]; [@bib99]). Exposure to ambient air pollution has been consistently associated with poor respiratory outcomes, including reduced FEV~1~ ([@bib15]; [@bib11]; [@bib47]; [@bib118]). We previously showed that exposure to sulfur dioxide (SO~2~), an air pollutant emitted by the burning of fossil fuels, is significantly associated with reduced FEV~1~ in African American children with asthma in the Study of African Americans, Asthma, Genes & Environments (SAGE II) study ([@bib77]). Because the genetic variants associated with FEV~1~ thus far do not account for the majority of its estimated heritability, considering gene--environment (GxE) interactions, specifically gene-by-air-pollution, may improve our understanding of lung function genetics ([@bib74]; [@bib75]). Here, we performed a genome-wide association analysis using WGS data to identify common genetic variants associated with FEV~1~ in African American children with asthma in SAGE II and investigated the effect of GxE (SO~2~) interactions on FEV~1~ associations.

Materials and Methods {#s1}
=====================

Study population {#s2}
----------------

This study examined African American children between 8--21 years of age with physician-diagnosed asthma from the SAGE II study. All SAGE II participants were recruited from the San Francisco Bay Area. The inclusion and exclusion criteria were previously described in detail ([@bib81]; [@bib117]). Briefly, participants were eligible if they were 8--21 years of age, self-identified as African American, and had four African American grandparents. Study exclusion criteria included the following: (1) any smoking within 1 year of the recruitment date; (2) 10 or more pack-years of smoking; (3) pregnancy in the third trimester; and (4) history of lung diseases other than asthma (for cases) or chronic illness (for cases and controls). Baseline lung function defined as FEV~1~ was measured by spirometry prior to administering albuterol, as previously described ([@bib81]).

Trans-Omics for Precision Medicine WGS data {#s3}
-------------------------------------------

SAGE II DNA samples were sequenced as part of the Trans-Omics for Precision Medicine (TOPMed) WGS program ([@bib104] *preprint*). WGS was performed at the New York Genome Center and Northwest Genomics Center on a HiSeq X system (Illumina, San Diego, CA) using a paired-end read length of 150 bp, with a minimum of 30× mean genome coverage. DNA sample handling, quality control, library construction, clustering and sequencing, read processing, and sequence data quality control are described in detail in the TOPMed website ([@bib124]). Variant calls were obtained from TOPMed data freeze 8 variant call format (VCF) files corresponding to the GRCh38 human genome assembly. Variants with a minimal read depth of 10 (DP10) were used for analysis unless otherwise stated.

Genetic principal components, global ancestry, and kinship estimation {#s4}
---------------------------------------------------------------------

Genetic principal components (PCs), global ancestry, and kinship estimation on genetic relatedness were computed using biallelic single-nucleotide polymorphisms (SNPs) with a PASS flag from TOPMed freeze 8 DP10 data. PCs and kinship estimates were computed using the PC-Relate function from the GENESIS R package ([@bib25], [@bib26]) using a workflow available from the Summer Institute in Statistical Genetics Module 17 course website ([@bib103]). African global ancestry was computed using the ADMIXTURE package ([@bib3]) in supervised mode using European (CEU), African (YRI), and Native American (NAM) reference panels as previously described ([@bib68]).

FEV~1~ GWAS {#s5}
-----------

Nonnormality of the distribution of FEV~1~ values was tested with the Shapiro--Wilk test in R using the shapiro.test function. Since FEV~1~ was not normally distributed (*P* = 1.41 × 10^−8^ for FEV~1~ and *P* = 1.05 × 10^−8^ for log~10~ FEV~1~), FEV~1~ was regressed on all covariates (age, sex, height, controller medications, sequencing centers, and the first five genetic PCs) and the residuals were inverse-normalized. These inverse-normalized residuals (FEV~1~.res.rnorm) were the main outcome of the discovery GWAS. The controller medication covariate included the use of inhaled corticosteroids (ICS), long-acting β-agonists (LABA), leukotriene inhibitors, and/or an ICS/LABA combo in the 2 weeks prior to the recruitment date.

Genome-wide single-variant analysis was performed on the ENCORE server (<https://github.com/statgen/encore>) using the linear Wald test (q.linear) originally implemented in EPACTS (<https://genome.sph.umich.edu/wiki/EPACTS>) and TOPMed freeze 8 data (DP0 PASS), with a minor allele frequency (MAF) filter of 0.1%. All pairwise relationships with degree three or more relatedness (kinship values \> 0.044) were identified, and one participant of the related pair was subsequently chosen at random and removed prior to analysis. All covariates used to obtain FEV~1~.res.rnorm were also included as covariates in the GWAS as recommended in a recent publication ([@bib100]). The association analysis was repeated using untransformed FEV~1~ and FEV~1~ percent predicted (FEV~1~.perc.predicted). FEV~1~ percent predicted was defined as the percentage of measured FEV~1~ relative to predicted FEV~1~, estimated by the Hankinson lung function prediction equation for African Americans ([@bib42]). A secondary analysis that included smoking-related covariates (smoking status and number of smokers in the family) was performed in PLINK 1.9 (version 1p9_2019_0304_dev) ([@bib92]; [@bib20]). To study whether association with FEV~1~ is specific to SAGE II participants with asthma, we repeated the association analysis adjusting for age, sex, height, and the first five genetic PCs in SAGE II participants without asthma on the ENCORE server. All of these participants were sequenced in the same center. Regional association results were plotted using LocusZoom 1.4 ([@bib91]) with a 500 kb flanking region. LD (*R*^2^) was estimated in PLINK 1.9. An LD plot was generated using recoded genotype files (plink --recode 12) in Haploview ([@bib12]).

The function effectiveSize in the R package CODA was used to estimate the actual effective number of independent tests, and CODA-adjusted statistical and suggestive significance *P*-value thresholds were defined as 0.05 and 1, divided by the effective number of tests, respectively ([@bib32]). We compared the CODA-adjusted statistical significance threshold and the widely used 5 × 10^−8^ GWAS genome-wide significance threshold ([@bib87]), and selected the more stringent threshold for genome-wide significance.

The following WGS quality control steps were applied to all reported variant association results from the ENCORE server to ensure WGS variant quality: (1) The variant had VCF FILTER = PASS; (2) variant quality was confirmed via manual inspection on the BRAVO server based on TOPMed freeze 5 data ([@bib110]); and (3) variants were reanalyzed with linear regression using PLINK 1.9 by applying the arguments --mac 5 --geno 0.1 --hwe 0.0001 using TOPMed freeze 8 DP10 PASS data.

To determine if the rs73429450 association with FEV~1~ was only identifiable using WGS data, we repeated the linear regression association analysis on signals that passed the genome-wide significance threshold using PLINK 1.9 and genotype data generated with the Axiom Genome-Wide LAT 1 array (Affymetrix, Santa Clara, CA; dbGaP phs000921.v1.p1). These array genotype data were imputed into the following reference panels: 1000 Genomes Project (1000G) phase 3 version 5, Haplotype Reference Consortium (HRC) r1.1, the Consortium on Asthma among African-ancestry Populations in the Americas (CAAPA), and the TOPMed phase 5 panels on the Michigan Imputation Server ([@bib29]). It should be noted that 500 SAGE II subjects were part of the TOPMed freeze 5 reference panel.

A total of 349 GWAS FEV~1~-associated entries were retrieved from the NHGRI-EBI GWAS Catalog version 1.0.2-associations_e98_r2020-03-08 ([@bib16]) using the trait names "Lung function (FEV~1~)", "FEV1," "Lung function (forced expiratory volume in 1 sec)," or "Prebronchodilator FEV1." After adding 100-kb flanking regions to each of the 349 entries, a total of 230 nonoverlapping region were obtained. To look up whether we replicated previous GWAS loci while control for multiple testing penalties, we only used 279,495 common variants (MAF ≥ 0.01) that overlapped with the 230 regions. The 279,495 common variants were equivalent to 17,755 effective tests based on CODA and 5.63 × 10^−5^ (1/17,755) was used as the suggestive *P*-value threshold for replication.

Conditional analysis {#s6}
--------------------

Conditional analysis was performed to identify all independent signals in a GWAS peak using PLINK 1.9. All TOPMed freeze 8 DP10 variants within 1 Mb of the tag association signal, and with association *P*-value of 1 × 10^−4^ or smaller in the discovery GWAS, were included in the analysis. Variants were first ordered by ascending *P*-value. A variant was considered to be an independent signal if the association *P*-value after conditioning (conditional *P*-value) on the tag signal was \< 0.05. Newly identified independent signals were included with the tag signal for conditioning on the next variant.

Region-based association analysis {#s7}
---------------------------------

Region-based association analyses were performed in 1-kb sliding windows with 500-bp increments in a 1-Mb flanking region of the tag GWAS signal using the SKAT_CommonRare function from the SKAT R package v1.3.2.1 ([@bib48]). Default settings were used with method = "C" and test.type = "Joint." A MAF threshold of 0.01 was used as the cutoff to distinguish rare and common variants. Variants were annotated in TOPMed using the Whole Genome Sequencing Annotator (WGSA) pipeline ([@bib66]). Since SKAT imputes missing genotypes by default by assigning mean genotype values (impute.method="fixed"), we chose to use low-coverage genotypes instead of SKAT imputation, and hence TOPMed freeze 8 DP0 variants with a VCF FILTER of PASS were included in the analysis. The function effectiveSize in the R package CODA ([@bib89]) was used to estimate the effective number of independent hypothesis tests for accurate Bonferroni multiple testing corrections. *P*-value thresholds for statistical significance and suggestive significance were defined as 0.05 and 1 divided by the effective number of tests, respectively ([@bib32]). If a region was suggestively significant, region-based analyses were repeated with functional variants and/or rare variants (MAF ≤ 0.01) to assess contributions of common, rare, and/or functional variants. Region-based analyses using rare variants only were performed using SKAT-O ([@bib60]). The WGSA annotation filters used to define functional variants are provided in Supplemental Material, File S1. To study the contribution of individual variants to a region-based association *P*-value, drop-one variant analysis was performed by repeating the region-based analysis multiple times and dropping one variant only at a time.

Functional annotations and prioritization of genetic variants {#s8}
-------------------------------------------------------------

The Hi-C Unifying Genomic Interrogator (HUGIN) ([@bib9]; [@bib96]; [@bib69]) was used to assign potential gene targets to each variant. HUGIN uses the Hi-C data generated from the primary human tissues from four donors used in the Roadmap Epigenomics Project ([@bib96]). Encyclopedia of DNA Elements (ENCODE) annotations ([@bib33], [@bib34]) were based on overlap of the variants with functional data downloaded from the University of California, Santa Cruz (UCSC) Table Browser ([@bib53]). These data included DNAase I hypersensitivity peak clusters (hg38 wgEncodeRegDnaseClustered table), transcription factor chromatin immunoprecipitation-sequencing (ChIP-Seq) clusters (hg38 encRegTfbsClustered table), and histone modification ChIP-Seq peaks (hg19 wgEncodeBroadHistone \<cell type\>\<histone\> StdPk tables). For DNase I hypersensitivity and transcription factor binding sites, we focused on blood, bone marrow, lung, and embryonic cells. For histone modification ChIP-Seq, we focused on H3K27ac and H3K4me3 modifications in human blood (GM12878), bone marrow (K562), lung fibroblast (NHLF), and embryonic stem cells (^1^H-hESC). The LiftOver tool ([@bib43]) was used to convert genomic coordinates from hg19 to hg38. Candidate *cis*-regulatory elements (ccREs) were a subset of representative DNase hypersensitivity sites with epigenetic activity further supported by histone modification (H3K4me3 and H3K27ac) or CTCF-binding data from the ENCODE project. Overlaps of variants with ccREs were detected using the Search Candidate *cis*-Regulatory Elements by ENCODE (SCREEN) web interface ([@bib33], [@bib34]).

Prioritization of genetic variants was based on the presence of statistical, functional, and/or bioinformatic evidence as described in the Diverse Convergent Evidence prioritization framework ([@bib23]). The priority score of each variant was obtained by counting the number of pieces of statistical, functional, and/or bioinformatic evidence that supported a potential biological function for that variant.

Replication of GWAS associations {#s9}
--------------------------------

All replication analyses were performed in subjects with asthma. Replication of GWAS FEV~1~ associations was attempted on TOPMed WGS data generated from four cohorts. These cohorts included Puerto Rican (*n* = 1109) and Mexican American (*n* = 649) children in the Genes-Environments and Admixture in Latino Americans (GALA II) study ([@bib81]), African American adults in the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE, *n* = 3428) ([@bib61]), and African American children in the Genetics of Complex Pediatric Disorders (GCPD-A, *n* = 1464) study ([@bib84]). Age, sex, height, controller medications, and the first five PCs were used as covariates.

Additionally, replication of GWAS FEV~1~ associations was attempted using data of black UK Biobank subjects who had asthma (*n* = 627) while adjusting for age, sex, height, and the first five PCs. Asthma status was defined by International Statistical Classification of Diseases and Related Health Problems (ICD) code of 493 or self-reported asthma. UK Biobank genotype data were generated on the Affymetrix UK BiLEVE axiom or UK Biobank Axiom array and imputed into the HRC, 1000G, and UK 10K projects ([@bib17]; [@bib18]). Additional details on the UK Biobank study and the replication procedures are available in File S1 (Text 2).

RNA sequencing and expression QTL analysis {#s10}
------------------------------------------

Whole-transcriptome libraries of 370 nasal brushings from GALA II Puerto Rican children with asthma were constructed by using the Beckman Coulter FX automation system (Beckman, Fullerton, CA). Libraries were sequenced with the Illumina HiSeq 2500 system. Raw RNA sequencing (RNA-Seq) reads were trimmed using Skewer ([@bib51]) and mapped to human reference genome hg38 using Hisat2 ([@bib55]). Reads mapped to genes were counted with htseq-count and using the UCSC hg38 Gene Transfer Format (GTF) file as reference ([@bib7]). *Cis*-expression QTL (eQTL) analysis of *KITLG* (KIT ligand) was performed as described in the Genotype-Tissue Expression (GTEx) project version 7 protocol (GTEx Consortium *et al.* 2017) using age, sex, body mass index, global African and European ancestries, and 60 probabilistic estimation of expression residual (PEER) factors as covariates.

Gene-by-air-pollution interaction analysis {#s11}
------------------------------------------

We hypothesized that the effect of genetic variation on lung function in our study population may differ by the levels of exposure to SO~2~ ([@bib77]). To test for an interaction between a genetic variant and SO~2~, an additional multiplicative interaction term (variant × S0~2~ exposure) was included in the original GWAS model (see section *FEV~1~ GWAS*). The SO~2~ estimates used in the interaction analysis were first-year, past-year, and lifetime exposure to ambient SO~2~, which were estimated as described previously ([@bib77]). Briefly, we obtained regional ambient daily air pollution data from the U.S. Environmental Protection Agency Air Quality System. SO~2~ estimates for each participant's residential geographic coordinate were calculated as the inverse distance-squared weighted average from the four closest air pollution monitoring stations within 50 km of the participant's residence. We estimated yearly exposure at the reported residential address by averaging all available daily measures (daily average of 1-hr SO~2~) in a given year. If the participant had a change of residential address in a given year, we estimate yearly exposure as a time-weighted estimate based on the number of months spent at each different address in that year. Average lifetime exposures were estimated using all available yearly average estimates over the lifetime of the participant until the day of spirometry testing. Since not all pollutants were measured daily, there are location- and pollutant-dependent missing values. Residuals of FEV~1~ were plotted against exposure to SO~2~ and stratified by the number of copies of the minor allele of a variant. Residuals of FEV~1~ were obtained as described in section *FEV~1~ GWAS*.

Data availability {#s12}
-----------------

Local institutional review boards approved the studies (number 10-02877). All subjects and legal guardians provided written informed consent. TOPMed WGS and phenotype data from SAGE II are available on dbGaP under accession number phs000921.v4.p1. Supplemental material and normalized gene count data for *KITLG* available at figshare: <https://doi.org/10.25386/genetics.12152196>.

Results {#s13}
=======

Novel lung function associations {#s14}
--------------------------------

Subject characteristics of the 867 African American children with asthma included in this study are shown in [Table 1](#t1){ref-type="table"}, and the distribution of their FEV~1~ measurements (mean = 2.56 L, SD = 0.79 L) is in Figure S1. The CODA-adjusted statistical significance thresholds 2.10 × 10^−8^ and 4.19 × 10^−7^ were used as the genome-wide and suggestive significance thresholds, respectively. According to this threshold, one SNP in chromosome 12 (chromosome 12:88846435, rs73429450, G \> A) was associated with FEV~1~.res.rnorm ([Figure 1](#fig1){ref-type="fig"}, *P* = 9.01 × 10^−9^, β = 0.801) at genome-wide significance. The association between rs73429450 and lung function remained statistically significant when the association was repeated using untransformed FEV~1~ (*P* = 1.26 × 10^−8^, β = 0.302) as the outcome variable. The association between rs73429450 and lung function was suggestive using FEV~1~.perc.predicted (*P* = 1.69 × 10^−7^, β = 0.100). Twenty suggestive associations corresponding to four tag signals are reported in File S2. None of the suggestive associations overlapped with any of the previously reported FEV~1~-associated loci. When considering only common variants and applying a *P*-value threshold of 5.63 × 10^−5^, we found replication in 6 out of 230 previously reported FEV~1~ associations (Table S1). Our top FEV~1~ association, rs73429450, did not overlap with any previously reported loci and it is a novel association with FEV~1~ in this study population.

###### Descriptive characteristics of 867 African American children with asthma included in this study

  Characteristic                              African American
  ------------------------------------------- ----------------------
  Age                                         
   Mean (SD)                                  14.1 (3.64)
   Median (25%, 75%)                          13.8 (10.98, 17.11)
  Sex                                         
   Male                                       439 (50.6%)
   Female                                     428 (49.4%)
  Height (m)                                  
   Mean (SD)                                  1.58 (0.145)
   Median (25%, 75%)                          1.60 (1.47, 1.68)
  Any control medications\* in last 2 weeks   
   No                                         543 (62.6%)
   Yes                                        324 (37.4%)
  ICS in last 2 weeks                         
   No                                         211 (24.3%)
   Yes                                        306 (35.3%)
   Missing                                    350 (40.4%)
  LABA in last 2 weeks                        
   No                                         5 (0.6%)
   Yes                                        94 (10.8%)
   Missing                                    768 (88.6%)
  Leukotriene inhibitor in last 2 weeks       
   No                                         11 (1.3%)
   Yes                                        68 (7.8%)
   Missing                                    788 (90.9%)
  African ancestry                            
   Mean (SD)                                  0.792 (0.129)
   Median (25%, 75%)                          0.826 (0.759, 0.869)
  Smoking status                              
   Never                                      793 (91.5%)
   Past                                       72 (8.3%)
   Current                                    0 (0%)
   Missing                                    2 (0.2%)
  Number of smokers in family                 
   0                                          469 (54.1%)
   1                                          137 (15.8%)
   2                                          42 (4.8%)
   3+                                         10 (1.2%)
   Missing                                    209 (24.1%)
  SO~2~ first year exposure (ppb)             
   Mean (SD)                                  1.59 (0.961)
   Median (25%, 75%)                          1.50 (1.24, 1.87)
   Missing                                    227 (26.2%)
  SO~2~ past year exposure (ppb)              
   Mean (SD)                                  1.10 (0.302)
   Median (25%, 75%)                          1.08 (0.910, 1.27)
   Missing                                    206 (23.8%)
  SO~2~ lifetime exposure (ppb)               
   Mean (SD)                                  1.50 (0.371)
   Median (25%, 75%)                          1.47 (1.40, 1.54)
   Missing                                    206 (23.8%)
  TOPMed sequencing center and phase          
   Phase 1, CAAPA                             6 (0.7%)
   Phase 1, NYGC                              460 (53.1%)
   Phase 3, NW                                401 (46.3%)

25% and 75%, 25th and 75th percentiles. Control medications include ICS, LABA, leukotriene inhibitor, and/or ICS/LABA combo. SO~2~ exposures are hourly exposures averaged over the specified time periods before spirometry testing, as previously described in [@bib77]. CAAPA, Consortium on Asthma among African-ancestry Populations in the Americas; NYGC, New York Genome Center; NW, Northwest Genomics Center; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; ppb, parts per billion or µg/m^3^; TOPMed, Trans-Omics for Precision Medicine.

![Manhattan and LocusZoom plots from genome-wide association study of lung function. (A) Manhattan plot from genome-wide association study of lung function using linear regression on the ENCORE server. FEV~1~.res.rnorm was used as the phenotype for the association testing. Red horizontal line: CODA-adjusted genome-wide significance *P*-value of 2.10 × 10^−8^. Blue horizontal line: CODA-adjusted suggestive significance *P*-value of 4.19 × 10^−7^. (B) LocusZoom plot of rs73429450 (chr12: 88846435) and 500-kb flanking region. Colors show linkage disequilibrium in the study population. chr12, chromosome 12; FEV~1~, forced expiratory volume in the first second of exhalation.](869f1){#fig1}

Secondary analysis that included covariates correcting for smoking status and number of smokers in the family showed that smoking-related factors were not significantly associated with FEV~1~ in our pediatric SAGE II cohort: using 657 out of 867 individuals with available smoking-related covariates, the FEV~1~.res.rnorm association *P*-values before and after including the smoking-related covariates were 2.01 × 10^−6^ and 1.89 × 10^−6^. Both *P*-values of the covariates smoking status (*P* = 0.27) and number of smokers in the family (*P* = 0.54) were not significant.

Conditional analysis was performed on 45 variants with association *P* \< 1 × 10^−4^ located within 1 Mb of the strongest association signal (rs73429450). Two weaker independent signals (rs17016065 and rs58475486) were identified (Table S2). None of the 45 variants showed association with FEV~1~.res.rnom in 251 SAGE II children without asthma (Table S3).

The minor allele frequency of rs73429450 in continental populations from the 1000G is 3% in Africans and \< 1% in Admixed Americans, Europeans, Asians (1000 Genomes Project Consortium *et al.* 2015). SNP rs73429450 was not included on the Affymetrix LAT 1 genotyping array where SAGE II participants were previously genotyped. To determine if the rs73429450 association with FEV~1~ was only identifiable using WGS data, we attempted to reproduce our results by imputing the genotype of rs73429450 in 851 SAGE II participants with available array data using 1000G phase 3 (*n* = 2504), HRC r1.1 (*n* = 32,470), CAAPA (*n* = 883), and TOPMed freeze 5 (*n* = 62,784) reference panels. Our results remained statistically significant when using the 1000G phase 3 (*P* = 4.97 × 10^−8^, β = 0.79, imputation *R*^2^ = 0.95) and TOPMed freeze 5 (*P* = 1.22 × 10^−8^, β = 0.80, imputation *R*^2^ = 0.98) reference panels, but lost statistical significance when rs73429450 genotypes were imputed using the HRC (*P* = 4.35 × 10^−7^, β = 0.68, imputation *R*^2^ = 0.94) and CAAPA (*P* = 1.95 × 10^−7^, β = 0.80, imputation *R*^2^ = 0.71) reference panels.

Region-based association analysis including all variants conditioned on the association signal from rs73429450 was performed in its 1-Mb flanking region (chromosome 12:87846435-89846435). No windows were significantly associated after Bonferroni multiple testing correction (*P* \< 2.80 × 10^−4^, Figure S2), but 20 windows were suggestively associated with FEV~1~.res.rnorm (*P* \< 5.60 × 10^−3^, Table S5). Two of 20 windows retested using only functional variants were suggestively significant (regions 4 and 16). Both of these windows were no longer suggestively significant after removing the common variants, indicating that association signals from these regions were mostly driven by common variants. Further investigation of region 16 using drop-one analysis of the two rare and one common function variants confirmed the major contribution by the common variant, rs1895710, as shown by the major increase in *P*-value (Table S6). The signal was also slightly driven by the singleton, rs990979778. Drop-one analysis was not performed on region 4 because there was only one common and one rare variant.

A Hi-C assay couples a chromosome conformation capture assay with next-generation sequencing to capture long-range interactions in the genome. We identified a statistically significant long-range chromatin interaction between the GWAS peak and the *KITLG* \[also known as stem cell factor (*SCF*)\] gene in human fetal lung fibroblast cell line IMR90 (Table S7). The long-range interaction detected in human primary lung tissue was not significant, implying that the potential long-range interactions are specific to tissue type or developmental stage.

Potential regulatory role of FEV~1~-associated variants on KITLG expression {#s15}
---------------------------------------------------------------------------

To further elucidate potential regulatory relationships between the GWAS association peak and *KITLG*, we analyzed whether variants in the peak were eQTL of *KITLG* in previously published whole-blood RNA-Seq data available from the same study participants ([@bib67]). However, the whole blood RNA-Seq data did not yield evidence of expressed *KITLG*, consistent with results in GTEx. We subsequently used RNA-Seq data from nasal epithelial cells of 370 Puerto Rican children with asthma from the GALA II study, and found that 5 out of 45 variants were eQTL of *KITLG* (Table S8). While Puerto Ricans are a different population compared with African Americans, they are both admixed populations with substantial African genetic ancestry, and therefore could share eQTLs. All five eQTLs corresponded to one signal in a region with strong LD (*r*^2^ \> 0.8, Figure S3).

Replication of genetic association with FEV~1~ {#s16}
----------------------------------------------

Subject characteristics of our four replication cohorts (SAPPHIRE, GCPD-A, UK Biobank, and GALA II) are shown in Table S9. We attempted to replicate the association of the 45 SNPs in our primary FEV~1~ GWAS in each cohort. We used 0.05 as the suggestive *P*-value threshold and 0.0167 as the Bonferroni-corrected *P*-value threshold after correcting for three independent signals (see conditional analysis in the *Results* section). A total of 20 variants were replicated at *P* \< 0.05 with consistent direction of effect in black UK Biobank participants; 14 variants in SAPPHIRE and 2 variants in GCPD-A were significant but had an opposite direction of effect (Table S10).

We attempted to replicate the FEV~1~.res.rnorm association in Mexican American (*n* = 649) and Puerto Rican (*n* = 1109) children with asthma from the GALA II study. In Mexican Americans, we excluded 19 variants with MAF \< 0.1% and associations for the remaining 26 variants did not replicate (Table S11). In Puerto Ricans, the associations were not replicated but we observed the same protective effect in 38 of the 45 variants in the locus (Table S11).

Incorporating statistical and functional evidence for candidate variant prioritization {#s17}
--------------------------------------------------------------------------------------

We combined and summarized all functional evidence for the top 45 variants, along with eQTL findings from nasal epithelial RNA-Seq and replication results ([Figure 2](#fig2){ref-type="fig"}, [Table 2](#t2){ref-type="table"}, and Table S12). To facilitate interpretation of the variant association with FEV~1~, the effect sizes and *P*-values of both FEV~1~ (β and *P*) and FEV~1~.res.rnorm (β~norm~ and *P*~norm~) associations are also reported. Combined Annotation Dependent Depletion (CADD) functional prediction score and ENCODE histone modification ChIP-Seq peaks in embryonic, blood, bone marrow, and lung-related tissues were also examined, but not reported because none of the variants had a CADD score \> 10 and none overlapped with histone modification sites. SNP rs73440122 received the highest priority score of 3 based on replication in the UK Biobank, overlap with a DNase I hypersensitivity site in B lymphoblastoid cells (GM12865), and overlap with an SPI1-binding site in acute promyelocytic leukemia cells. Eight other variants were prioritized with a score \> 2 or evidence of being an eQTL for *KITLG* in nasal epithelial cells ([Table 2](#t2){ref-type="table"}, score marked with \^ or \#, respectively). These nine candidate variants were selected for gene-by-air-pollution interaction analyses.

![Integration of statistical and functional evidence for variant prioritization. Numbers and different shades of black in the LD plot represent LD in R^2^. The three independent signals identified in the conditional analysis are marked with "\*". Insertions/deletions are marked with "^&^". Nasal eQTL, eQTLs of *KITLG* in nasal epithelial cells. ENCODE, DNase I hypersensitivity site and/or transcription factor ChIP-Seq peaks overlapping with the variants. UK Biobank, SAPPHIRE, and GCPD-A: replication results using blacks in the UK Biobank and African Americans in the SAPPHIRE and GCPD-A cohorts (*R* = replicated at *P* \< 0.05; F = flip-flop association at *P* \< 0.05). Candidate, candidate variants prioritized because of presence of two or more pieces of evidence, or because they are a nasal eQTL. + indicates presence of evidence. Boxes in the top panel were shaded gray if results were not available. ccREs, candidate *cis*-regulatory elements in SCREEN registry; ChIP-Seq, chromatin immunoprecipitation sequencing; ENCODE, Encyclopedia of DNA Elements; eQTL, expression QTL; GCPD-A, Genetics of Complex Pediatric Disorders study; LD, linkage disequilibrium; SAPPHIRE, Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity; SCREEN, Search Candidate *cis*-Regulatory Elements by ENCODE.](869f2){#fig2}

###### Genome-wide lung function association in SAGE II children with asthma

                                                                                                           1000 Genomes                           
  ---- ------------------------------------------------- --- ------- ---------- ------- ---------- ------- -------------- ------- ------- ------- -----
  1    rs11835305                                        T   0.126   1.93E-05   0.320   3.69E-05   0.104   0.036          0.119   0.012   0.001   0
  2    rs17015963                                        C   0.126   1.93E-05   0.320   3.69E-05   0.104   0.036          0.120   0.012   0.001   0
  3    rs58475486[*^a^*](#t2n1){ref-type="table-fn"}     T   0.127   1.45E-05   0.323   2.81E-05   0.105   0.037          0.123   0.012   0.001   2\^
  4    rs17015979                                        T   0.127   1.45E-05   0.323   2.81E-05   0.105   0.037          0.123   0.012   0.001   0
  5    rs57692452                                        C   0.245   1.63E-06   0.654   1.06E-06   0.033   0.011          0.030   0.006   0.001   2\^
  6    rs112585732                                       T   0.235   4.35E-07   0.625   3.06E-07   0.041   0.016          0.050   0.006   0.001   0
  7    rs113837356                                       T   0.270   3.44E-06   0.719   2.49E-06   0.025   0.008          0.027   0.006   0.001   1
  8    rs61441836                                        G   0.252   8.19E-07   0.671   5.46E-07   0.033   0.010          0.030   0.006   0.001   1
  9    rs73438172                                        A   0.252   8.19E-07   0.671   5.46E-07   0.033   0.010          0.030   0.006   0.001   1
  10   rs1044043958[*^b^*](#t2n2){ref-type="table-fn"}   A   0.270   3.44E-06   0.719   2.49E-06   0.025   ---            ---     ---     ---     0
  11   rs73438182                                        G   0.138   1.68E-04   0.378   9.18E-05   0.064   0.020          0.068   0.006   0.001   0
  12   rs73438185                                        A   0.138   1.68E-04   0.378   9.18E-05   0.064   0.020          0.068   0.006   0.001   0
  13   rs73438188                                        A   0.297   6.97E-08   0.792   4.42E-08   0.028   0.010          0.027   0.006   0.001   1
  14   rs73438190                                        C   0.181   1.86E-05   0.486   1.22E-05   0.048   0.016          0.047   0.006   0.001   0
  15   rs73438195                                        A   0.181   1.86E-05   0.486   1.22E-05   0.048   0.016          0.047   0.006   0.001   0
  16   rs111857459                                       T   0.181   1.86E-05   0.486   1.22E-05   0.048   0.016          0.047   0.006   0.001   0
  17   rs144369986[*^b^*](#t2n2){ref-type="table-fn"}    T   0.285   1.21E-06   0.756   9.44E-07   0.025   0.008          0.026   0.006   0.001   0
  18   rs73440106                                        G   0.181   1.86E-05   0.486   1.22E-05   0.048   0.016          0.047   0.006   0.001   0
  19   rs73440107                                        A   0.297   6.97E-08   0.792   4.42E-08   0.028   0.010          0.027   0.006   0.001   1
  20   rs111453514                                       C   0.297   6.97E-08   0.792   4.42E-08   0.028   0.010          0.027   0.006   0.001   1
  21   rs73440112                                        T   0.297   6.97E-08   0.792   4.42E-08   0.028   0.010          0.027   0.006   0.001   1
  22   rs73440115                                        G   0.297   6.97E-08   0.792   4.42E-08   0.028   0.011          0.028   0.006   0.001   1
  23   rs11312747[*^b^*](#t2n2){ref-type="table-fn"}     A   0.133   1.43E-05   0.357   8.51E-06   0.100   0.036          0.121   0.010   0.001   0
  24   rs73440120                                        A   0.285   1.21E-06   0.756   9.44E-07   0.025   0.008          0.026   0.006   0.001   1
  25   rs111289668                                       G   0.297   6.97E-08   0.792   4.42E-08   0.028   0.010          0.027   0.006   0.001   2\^
  26   rs73440122                                        C   0.292   2.08E-07   0.775   1.55E-07   0.027   0.011          0.030   0.006   0.001   3\^
  27   rs73440123                                        G   0.292   2.08E-07   0.775   1.55E-07   0.027   0.011          0.030   0.006   0.001   1
  28   rs17016065[*^a^*](#t2n1){ref-type="table-fn"}     G   0.112   3.19E-06   0.296   2.54E-06   0.177   0.075          0.217   0.017   0.009   1\#
  29   rs17016066                                        A   0.112   3.19E-06   0.296   2.54E-06   0.177   0.075          0.217   0.017   0.009   1\#
  30   rs147400083[*^b^*](#t2n2){ref-type="table-fn"}    T   0.112   3.19E-06   0.296   2.54E-06   0.177   ---            ---     ---     ---     0
  31   rs866852270                                       T   0.112   3.19E-06   0.296   2.54E-06   0.177   ---            ---     ---     ---     0
  32   rs141293300[*^b^*](#t2n2){ref-type="table-fn"}    C   0.292   2.08E-07   0.775   1.55E-07   0.027   0.011          0.030   0.006   0.001   1
  33   rs1398303                                         A   0.104   1.22E-05   0.274   1.12E-05   0.186   0.077          0.223   0.020   0.009   1\#
  34   rs61924868                                        T   0.104   1.24E-05   0.275   1.14E-05   0.185   0.078          0.223   0.020   0.009   1\#
  35   rs73440134                                        T   0.292   2.08E-07   0.775   1.55E-07   0.027   0.011          0.030   0.006   0.001   1
  36   rs73429413                                        G   0.292   2.08E-07   0.775   1.55E-07   0.027   0.011          0.030   0.006   0.001   1
  37   rs73429415                                        A   0.096   5.13E-05   0.253   4.84E-05   0.189   0.078          0.225   0.022   0.009   1\#
  38   rs112449284                                       T   0.242   4.64E-06   0.640   3.87E-06   0.031   0.012          0.035   0.007   0.001   1
  39   rs111981782                                       C   0.296   5.78E-08   0.786   4.09E-08   0.029   0.012          0.033   0.006   0.001   1
  40   rs150942400                                       T   0.293   6.01E-08   0.780   4.01E-08   0.029   0.012          0.034   0.006   0.002   1
  41   rs147527487                                       C   0.086   8.49E-05   0.226   8.14E-05   0.205   0.095          0.249   0.016   0.005   0
  42   rs111243672                                       A   0.258   6.41E-07   0.690   3.99E-07   0.032   0.014          0.037   0.007   0.004   1
  43   rs73429450[*^a^*](#t2n1){ref-type="table-fn"}     A   0.302   1.26E-08   0.801   9.01E-09   0.031   0.012          0.033   0.009   0.002   1
  44   rs758775577                                       C   0.217   2.22E-06   0.574   1.85E-06   0.041   ---            ---     ---     ---     0
  45   rs142679473[*^b^*](#t2n2){ref-type="table-fn"}    C   0.285   6.30E-08   0.756   4.62E-08   0.031   0.012          0.033   0.009   0.002   0

Score, priority score based on statistical and functional evidence, which is reported in Table S12. M, marker number that corresponds to those in [Figure 2](#fig2){ref-type="fig"} and Table S12. Candidate variants were prioritized if they had a priority score of \> 2 (\^) or if they were expression QTL of KITLG in nasal epithelial cells (\#). β (*P*) and β~norm~ (*P*~norm~) are the effect sizes (*P*-values) of the genetic associations of the alternate allele (Alt) with FEV~1~ and FEV~1~.res.rnorm, respectively. ALL/AFR/AMR/EUR, 1000 Genomes minor allele frequency from all/African/American/European populations. ---, not available. MAF, minor allele frequency.

The three independent signals identified in the conditional analyses.

Insertions/deletions.

Gene-by-air-pollution interaction of rs58475486 {#s18}
-----------------------------------------------

We previously found that first year of life and lifetime exposure to SO~2~ were associated with FEV~1~ in African American children ([@bib77]). We investigated whether the effect of the nine prioritized genetic variants associated with lung function varied by SO~2~ exposure (first year of life, past-year, and lifetime exposure). Since the nine variants represent three independent signals (see conditional analysis in the *Results* section), the Bonferroni-corrected *P*-value threshold was set to *P* = 0.0056 (correction for nine tests; three signals and three exposure periods to SO~2~). We observed a single statistically significant interaction between the T allele of rs58475486 and past-year exposure to SO~2~ that was positively associated with FEV~1~ (*P* = 0.003, β = 0.32; [Figure 3A](#fig3){ref-type="fig"} and [Table 3](#t3){ref-type="table"}). This interaction remained significant (*P* = 0.003, β = 0.32) in secondary analyses adjusted for smoking status, or a multiplicative interaction term of rs58475486 and smoking status as additional covariates. Interestingly, six of the remaining eight variants also displayed interaction effects with past-year exposure to SO~2~ that were suggestively associated (*P* \< 0.05) with FEV~1~ ([Table 3](#t3){ref-type="table"}). We also found a suggestive interaction of the C allele of rs73440122 with first-year exposure to SO~2~ that was associated with decreased FEV~1~ (*P* = 0.045, β = −0.32; [Figure 3B](#fig3){ref-type="fig"}). The same allele also showed interaction with past year of exposure to SO~2~ that was suggestively associated with FEV~1~ in the opposite direction (*P* = 0.051, β = 0.39).

![Gene-by-environment interaction analysis on FEV~1~. FEV~1~ residuals, residuals after FEV~1~ was regressed on the covariates age, sex, height, controller medications, sequencing centers, and the first five genetic PCs. FEV~1~ residuals were plotted against (A) past-year exposure to SO~2~ stratified by the number of copies of T allele of rs58475486 and (B) first year of life exposure to SO~2~ stratified by the number of copies of C allele of rs73440122. FEV~1~, forced expiratory volume in the first second of exhalation; PC, principal component.](869f3){#fig3}

###### Gene-and-environment analysis on FEV~1~

  Variant                                               Exposure           *n*   Variant   Exposure   GxE                     
  ----------------------------------------------------- ------------------ ----- --------- ---------- ------- ------- ------- -------
  rs58475486_T^1^                                       SO~2~ first year   640   0.13      6.62E-06   −0.05   0.003   −0.03   0.658
  rs57692452_C^2^                                       SO~2~ first year   640   0.25      1.16E-06   −0.05   0.003   −0.24   0.091
  rs111289668_G^2^                                      SO~2~ first year   640   0.31      2.53E-08   −0.05   0.003   −0.27   0.079
  rs73440122_C^2^[*^a^*](#t3n1){ref-type="table-fn"}    SO~2~ first year   640   0.31      7.78E-08   −0.05   0.003   −0.32   0.045
  rs17016065_G^3^                                       SO~2~ first year   640   0.11      8.82E-06   −0.05   0.003   −0.08   0.108
  rs17016066_A^3^                                       SO~2~ first year   640   0.11      8.82E-06   −0.05   0.003   −0.08   0.108
  rs1398303_A^3^                                        SO~2~ first year   640   0.10      3.15E-05   −0.05   0.003   −0.09   0.082
  rs61924868_T^3^                                       SO~2~ first year   640   0.10      3.30E-05   −0.05   0.003   −0.08   0.088
  rs73429415_A^3^                                       SO~2~ first year   640   0.09      1.09E-04   −0.05   0.003   −0.09   0.069
  rs58475486_T^1^[*^b^*](#t3n2){ref-type="table-fn"}    SO~2~ past year    661   0.13      6.62E-06   0.05    0.362   0.32    0.003
  rs57692452_C^2^                                       SO~2~ past year    661   0.25      1.16E-06   0.05    0.362   0.29    0.100
  rs111289668_G^2^[*^a^*](#t3n1){ref-type="table-fn"}   SO~2~ past year    661   0.31      2.53E-08   0.05    0.362   0.41    0.037
  rs73440122_C^2^                                       SO~2~ past year    661   0.31      7.78E-08   0.05    0.362   0.39    0.051
  rs17016065_G^3^[*^a^*](#t3n1){ref-type="table-fn"}    SO~2~ past year    661   0.11      8.82E-06   0.05    0.362   0.20    0.026
  rs17016066_A^3^[*^a^*](#t3n1){ref-type="table-fn"}    SO~2~ past year    661   0.11      8.82E-06   0.05    0.362   0.20    0.026
  rs1398303_A^3^[*^a^*](#t3n1){ref-type="table-fn"}     SO~2~ past year    661   0.10      3.15E-05   0.05    0.362   0.21    0.021
  rs61924868_T^3^[*^a^*](#t3n1){ref-type="table-fn"}    SO~2~ past year    661   0.10      3.30E-05   0.05    0.362   0.21    0.023
  rs73429415_A^3^[*^a^*](#t3n1){ref-type="table-fn"}    SO~2~ past year    661   0.09      1.09E-04   0.05    0.362   0.20    0.026
  rs58475486_T^1^                                       SO~2~ lifetime     661   0.13      6.62E-06   −0.13   0.001   0.26    0.173
  rs57692452_C^2^                                       SO~2~ lifetime     661   0.25      1.16E-06   −0.13   0.001   0.47    0.221
  rs111289668_G^2^                                      SO~2~ lifetime     661   0.31      2.53E-08   −0.13   0.001   0.32    0.444
  rs73440122_C^2^                                       SO~2~ lifetime     661   0.31      7.78E-08   −0.13   0.001   0.29    0.489
  rs17016065_G^3^                                       SO~2~ lifetime     661   0.11      8.82E-06   −0.13   0.001   −0.19   0.143
  rs17016066_A^3^                                       SO~2~ lifetime     661   0.11      8.82E-06   −0.13   0.001   −0.19   0.143
  rs1398303_A^3^                                        SO~2~ lifetime     661   0.10      3.15E-05   −0.13   0.001   −0.17   0.184
  rs61924868_T^3^                                       SO~2~ lifetime     661   0.10      3.30E-05   −0.13   0.001   −0.17   0.199
  rs73429415_A^3^                                       SO~2~ lifetime     661   0.09      1.09E-04   −0.13   0.001   −0.16   0.207

*n*, sample sizes for the gene-by-SO~2~ interaction analysis. Superscript 1 to 3 in the variant column, variants that are in linkage disequilibrium with the three independent signals, rs58475486, rs73429450, and rs17016065, respectively. β (*P*), effect sizes (*P* - values) from the main effects of the variants, exposure, and GxE interaction. GxE, gene--environment interaction.

GxE *P* \< 0.05.

GxE *P* \< Bonferroni *P*-value of 0.0056.

Discussion {#s19}
==========

Variant rs73429450 (MAF = 0.030) was identified as the strongest association signal with FEV~1~. Each additional copy of the protective A allele of rs73429450 was associated with a 0.3 L increase of FEV~1~. We did not find any statistically significant contribution of rare variants to the association signal from a 1-kb sliding window analyses in the 1-MB flanking region centered on rs73429450. We were surprised to identify a novel common variant (MAF = 0.030) associated with lung function using WGS data in a population that was previously analyzed for associations with lung function using genotype array data. Further investigation revealed that our discovered variant, rs73429450, was not captured by the LAT 1 genotyping array, and the association with lung function depended on the reference panel used to impute the variant into our population. More surprisingly, our statistically significant finding was only found to be suggestively significant using data imputed from the CAAPA reference panel (*P* = 1.95 × 10^−7^, β = 0.80). Of the imputation reference panels that we assessed, CAAPA is one of the more relevant reference panels for our study population because it is based on African populations in the Americas. However, we note that the effect size estimated from CAAPA-imputed data was comparable to that generated from WGS data. While WGS data are usually praised for enabling analysis of rare-variant contributions to phenotype variability, our results show the utility of WGS data for the reliable analysis of common variants as well as in the absence of relevant imputation panels.

Although rs73429450 had the lowest *P*-value from our WGS association analysis, we did not find the required amount of functional evidence to prioritize this marker for inclusion in downstream gene-by-air-pollution analyses. Another variant, rs73440122, was in moderate-to-strong LD (*r*^2^ = 0.76) with rs73429450 and had a similar MAF (0.027) in our study population, but was only suggestively associated with FEV~1~ in our association analysis (*P* = 2.08 × 10^−7^; [Table 2](#t2){ref-type="table"}). In contrast to rs73429450, there were multiple lines of evidence suggesting the functional relevance of rs73440122: rs73440122 received the highest priority score based on its replicated FEV~1~ association in black UK Biobank participants and overlap with ENCODE gene regulatory regions, making it one of the most likely drivers of FEV~1~ variability among individuals, possibly mediated through *KITLG*.

Bioinformatic interrogation of rs73440122 revealed that the variant overlapped with a ccRE (SCREEN accession EH37E0279310), DNase I hypersensitivity site, and SPI1 ChIP-Seq clusters that were indicative of a candidate open chromatin gene regulatory region (Table S12). The binding evidence of SPI1 is highly relevant to the role of KITLG in type 2 inflammation (see below). Variant rs73440122 is located in a region that physically interacts with *KITLG* based on Hi-C data in fetal lung fibroblast cells. Additionally, five neighboring FEV~1~ associated variants were identified as eQTLs of *KITLG*, although they appeared to be an independent signal (*r*^2^ \< 0.2). Overall, these results support regulatory interactions between our novel locus and *KITLG*.

Atopic or type 2 high asthma is the most common form of asthma in children ([@bib24]). *KITLG*, more commonly known as *SCF*, is a ligand of the KIT tyrosine kinase receptor. It plays an important role in type 2 inflammation in atopic asthma, especially in inflammatory processes mediated through mast cells, IgE, and group 2 innate lymphoid cells ([@bib83]; [@bib30]; [@bib31]; [@bib36]). In the airways, *KITLG* is expressed in bronchial epithelial cells, lung fibroblasts, bronchial smooth muscle cells, endothelial cells, peripheral blood eosinophils, dendritic cells, and mast cells ([@bib112]; [@bib116]; [@bib54]; [@bib44]; [@bib85]). *KITLG* is a major growth factor of mast cells \[reviewed in [@bib37], [@bib38]), [@bib14]), and [@bib31])\]. It promotes recruitment of mast cell progenitors into tissues \[reviewed in [@bib83])\], prevents mast cell apoptosis ([@bib72]; [@bib46]), and promotes release of inflammatory mediators such as proteases, histamine, chemotactic factors, and cytokines \[reviewed in [@bib13]) and [@bib6])\]. While KITLG promotes the production of cytokines like IL-13 upon IgE-receptor cross-linking on the surface of mast cells ([@bib57]), IL-13 has also been reported to upregulate *KITLG* ([@bib95]). Consistent with the critical role of KITLG for mast cells and type 2 inflammation, we found our prioritized variant, rs73440122, overlapped with an SPI1 (also known as PU.1) ChIP-Seq cluster. The transcription factor SPI1 was demonstrated in SPI1 knockout mice to be necessary for the development of B cells, T cells, neutrophils, macrophages, dendritic cells, and mast cells ([@bib97], [@bib98]; [@bib71]; [@bib8]; [@bib41]; [@bib114]). It plays an essential role in macrophage differentiation in asthmatic and other allergic inflammation ([@bib93]; [@bib122]). It was also shown to regulate the cell fate between mast cells and monocytes ([@bib79],[@bib80]; [@bib49], [@bib50]). The presence of an SPI1 binding site in a candidate regulatory region of *KITLG* is therefore highly relevant given the critical role of KITLG in mast cell survival and activation.

Higher levels of KITLG ([@bib4]; [@bib31]; [@bib105]) and an increased number of mast cells in the lung ([@bib35]; [@bib27]; [@bib73]) were detected in individuals with asthma. The percentage of a subpopulation of circulating blood mast cell progenitors (Lin^+^ CD34^hi^ CD117^int/hi^ FcεRI^+^) was higher in individuals with reduced lung function ([@bib28]). These findings suggested that higher *KITLG* expression and/or number of mast cells may be a contributing factor to lower lung function. This notion was inconsistent with the association of our novel locus with higher *KITLG* expression and increased lung function in SAGE II children with asthma. Interestingly, a study of 20 subjects with severe asthma found that an increase in the number of chymase-positive mast cells in the small airway was associated with increased lung function ([@bib10]). Overall, while there is still controversy on the direction of effect, previous findings support the association of our novel *KITLG* locus with lung function, especially in patients with allergic asthma. Our novel locus likely represents part of a complex regulatory mechanism that modulates immune cell differentiation, survival, and activation in highly cell-specific and context-dependent manners. Further studies are required to study how this locus is regulated in different airway and immune cells to affect lung function outcome in the context of asthma.

GxE interactions likely account for a portion of the "missing" heritability of many complex phenotypes ([@bib75]). We previously found that lung function in SAGE II participants was associated with first year of life and lifetime exposures to SO~2~ \[1.66% decrease (95% C.I. = −2.92 to −0.37) for first year of life and 5.30% decrease (95% C.I. = −8.43 to −2.06) for lifetime exposures in FEV~1~ per 1 ppb increases in SO~2~\] ([@bib77]). We hypothesized that a significant portion of the heritability of lung function was due, in part, to gene-by-air-pollution (SO~2~) interaction effects. The interaction between rs58475486 and past-year exposure to SO~2~ that was significantly associated with lung function supports our hypothesis. The T allele of rs58475486 is common (8--14%) in African populations and showed a protective effect on lung function in the presence of past-year SO~2~ exposure. SNP rs58475486 is located in a ccRE (SCREEN accession EH37E0279296) and a FOXA1 binding site in the A549 lung adenocarcinoma cell line. FOXA1 has a known compensatory role with FOXA2 during lung morphogenesis in mice ([@bib115]). Deletion of both FOXA1 and FOXA2 inhibited cell proliferation, epithelial cell differentiation, and branching morphogenesis in fetal lung tissue. Further functional validation of the effect of rs58475486 on the binding affinity of FOXA1 is necessary to confirm whether the role of FOXA1 in this ccRE is important for *KITLG* regulatory and lung function.

The higher frequencies of the protective alleles of both rs73440122 and rs58465486 in African populations appear to contradict previous findings that African ancestry is associated with lower lung function ([@bib59]). One possible explanation for this seeming inconsistency is that FEV~1~ is a complex trait, whose variation is influenced by many genetic variants of small-to-moderate effect sizes whose influences on lung function may vary by exposure to environmental factors. We found suggestive evidence that the interaction between rs73440122 and first-year exposure to SO~2~ reverses the positive association of rs73440122 with lung function to a negative one ([Table 3](#t3){ref-type="table"}). When assessed independently, our genetic association analysis showed that the protective A allele of rs73440122 was associated with higher lung function. However, with increasing levels of SO~2~ exposure in the first year of life, increasing copies of the A allele of rs73440122 were associated with decreased lung function. Air pollution is known to negatively impact lung function, and we have previously shown that the deleterious effects of air pollution on lung phenotypes may be significantly increased in African American children compared to other populations experiencing the same amount of exposure ([@bib78]). It has also been reported that Latino and African American populations often live in neighborhoods with high levels of air pollution ([@bib76]). The increased susceptibility to negative pulmonary effects from air pollution exposure coupled with the disproportionate exposure to air pollution experienced by the African American population may also contribute to the lower lung function seen in this population, despite the presence of protective alleles. The overlap of the SPI1 binding site with rs73440122 further supports gene-by-SO~2~ interaction at this locus, since SPI1 plays a critical role in the development of type 2 inflammation in the airways through macrophage polarization ([@bib93]). We noted that the rs73440122 A allele also showed an interaction approaching suggestive threshold with past-year exposure to SO~2~ that was positively associated with FEV~1~. The difference is not surprising because age of exposure may significantly impact the effect of air pollution on lung function \[reviewed in [@bib111]\]. Further studies are required to better understand the effect of this suggestive interaction on lung function.

One strength of this study is the interrogation of independent lung function-associated signals at our novel locus. We identified evidence of three independent signals: the replicated signal that showed evidence of regulatory functions (an open chromatin region with an SPI1/PU.1 binding site), one signal that showed a statistically significant gene-by-SO~2~ interaction on lung function, and one signal that represents *KITLG* eQTLs in the nasal epithelial cells together with suggestive gene-by-SO~2~ interaction. Our results demonstrate a glimpse of the complicated genetic architecture behind complex traits.

One limitation of this study is that the FEV~1~ genetic association and the eQTL analyses with *KITLG* were performed in different populations due to data availability constraints. Although we did not have RNA-Seq data from lung tissues from our study subjects, we previously demonstrated that there is a high degree of overlap in gene expression profiles between nasal and bronchial epithelial cells ([@bib90]). The direction of effect of the association was the same in GALA II Puerto Rican children with asthma but not statistically significant. This may be due to: (1) the lower minor allele frequency in Puerto Ricans with significantly lower African Ancestry compared to African Americans, and (2) the modest sample size of the replication study and the weak effect of the protective allele can lead to undetectable true associations ([@bib5]).

We replicated 20 of 45 variants in black UK Biobank subjects and observed conflicting "flip-flop" associations in African Americans from the SAPPHIRE and GCPD-A studies. In the past, flip-flop associations were deemed as spurious results. The traditional association-testing approach studies the effect of each variant on phenotype independently and increases the chance of flip-flop associations detected between studies. Differences in study design, sampling variation that leads to variation in LD patterns, and lack of consideration of other disease-influencing genetic and/or environmental factors are all potential causes of flip-flop associations ([@bib64]; [@bib58]). Hence, it is not surprising that flip-flop associations were observed when gene and environment interactions were detected at our FEV~1~ GWAS locus. It was previously shown that flip-flop associations can occur between and within populations, even in the presence of a genuine genetic effect ([@bib64]; [@bib58]). Further functional analysis is thus required to validate the relationship between the candidate variants *KITLG* and FEV~1~. This may include reporter assays to validate potential enhancer or repressor activity, and clustered regularly interspaced short palindromic repeats-based editing assays to validate the regulatory role of the candidate variants on *KITLG*. Although literature exists describing KIT signaling for lung function in mice ([@bib65]), additional knockout experiments in a model animal system are necessary to study how *KITLG* contributes to variation in lung function.

The average concentration of ambient SO~2~ exposure in our participants ([Table 1](#t1){ref-type="table"}) was lower than National Ambient Air Quality Standards. It is possible that SO~2~ acted as a surrogate for other unmeasured toxic pollutants emitted from local point sources. Major sources of SO~2~ in the San Francisco Bay Area during the recruitment years of 2006--2011 include airports, petroleum refineries, gas and oil plants, calcined petroleum coke plants, electric power plants, cement manufacturing factories, chemical plants, and landfills ([@bib108], [@bib109]). The Environmental Protection Agency's national emissions inventory data also show that these facilities emit volatile organic compounds, heavy metals (lead, mercury, chromium, and arsenic), formaldehyde, ethyl benzene, acrolein, 1,3-butadiene, 1,4-dichlorobenzene, and tetrachloroethylene into the air along with SO~2~. These chemicals are highly toxic and inhaling even a small amount may contribute to poor lung function. Another possibility is that exposure to SO~2~ captures unmeasured confounding socioeconomic factors.

This study identified a novel protective allele for lung function in African American children with asthma. The protective association with lung function intensified with increased past-year exposure to SO~2~. Our findings showcase the complexity of the relationship between genetic and environmental factors impacting variation in FEV~1~, highlights the utility of WGS data for genetic research of complex phenotypes, and underscores the importance of including diverse study populations in our exploration of the genetic architecture underlying lung function.
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